NL192917C - Stabiele farmaceutische bereiding die granulocytkolonie-stimulerende factor bevat. - Google Patents

Stabiele farmaceutische bereiding die granulocytkolonie-stimulerende factor bevat. Download PDF

Info

Publication number
NL192917C
NL192917C NL8701640A NL8701640A NL192917C NL 192917 C NL192917 C NL 192917C NL 8701640 A NL8701640 A NL 8701640A NL 8701640 A NL8701640 A NL 8701640A NL 192917 C NL192917 C NL 192917C
Authority
NL
Netherlands
Prior art keywords
csf
pharmaceutical preparation
serum albumin
stable pharmaceutical
polyoxiethylene
Prior art date
Application number
NL8701640A
Other languages
English (en)
Dutch (nl)
Other versions
NL8701640A (nl
NL192917B (nl
Inventor
Minoru Machida
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NL8701640A publication Critical patent/NL8701640A/nl
Publication of NL192917B publication Critical patent/NL192917B/xx
Application granted granted Critical
Publication of NL192917C publication Critical patent/NL192917C/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NL8701640A 1986-07-18 1987-07-13 Stabiele farmaceutische bereiding die granulocytkolonie-stimulerende factor bevat. NL192917C (nl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP16948686 1986-07-18
JP16948686 1986-07-18
JP16948886 1986-07-18
JP16948786 1986-07-18
JP16948786 1986-07-18
JP16948986 1986-07-18
JP16948886 1986-07-18
JP16948986 1986-07-18

Publications (3)

Publication Number Publication Date
NL8701640A NL8701640A (nl) 1988-02-16
NL192917B NL192917B (nl) 1998-01-05
NL192917C true NL192917C (nl) 1998-05-07

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8701640A NL192917C (nl) 1986-07-18 1987-07-13 Stabiele farmaceutische bereiding die granulocytkolonie-stimulerende factor bevat.

Country Status (24)

Country Link
KR (1) KR930004597B1 (ko)
CN (1) CN1033738C (ko)
AT (1) AT402259B (ko)
AU (1) AU611856B2 (ko)
BE (1) BE1000253A3 (ko)
CA (1) CA1297007C (ko)
CH (1) CH671157A5 (ko)
DE (1) DE3723781C2 (ko)
DK (1) DK171308B1 (ko)
ES (1) ES2010226A6 (ko)
FR (1) FR2601591B1 (ko)
GB (1) GB2193631B (ko)
GR (1) GR871067B (ko)
HK (1) HK64893A (ko)
HU (1) HU198627B (ko)
IE (1) IE60290B1 (ko)
IL (1) IL83220A (ko)
IT (1) IT1218927B (ko)
NL (1) NL192917C (ko)
NO (1) NO171828C (ko)
PT (1) PT85343B (ko)
SE (1) SE503312C2 (ko)
SG (1) SG64393G (ko)
YU (1) YU47543B (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NO179479C (no) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
EP0582932A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Inst Arzneimittelformulierungen für il-12
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6776983B1 (en) * 1998-03-06 2004-08-17 Chugai Seiyaku Kabushiki Kaisha Protein free formulations
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
AU6875900A (en) 1999-09-08 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
DE60103940T2 (de) * 2000-02-29 2005-07-28 Pfizer Products Inc., Groton Stabilisierter Granulozyten-Kolonie-stimulierender Faktor
AU2001236005A1 (en) * 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1329224A4 (en) 2000-09-01 2004-04-14 Chugai Pharmaceutical Co Ltd PREPARATIONS OF STABILIZED SOLUTIONS OVER A LONG PERIOD OF TIME
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP2094274A4 (en) 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR BONE MARROW RECOVERY
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
BR112012017979B1 (pt) * 2010-01-19 2021-10-13 Hanmi Science Co., Ltd. Formulações líquidas para conjugado de g-csf de ação prolongada
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
ES2830726T3 (es) 2016-02-23 2021-06-04 Biolinerx Ltd Método para seleccionar un régimen de tratamiento para la leucemia mieloide aguda (LMA)
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
US20210196568A1 (en) * 2018-05-21 2021-07-01 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass container

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
SE451844B (sv) * 1978-03-20 1987-11-02 Morinaga Milk Industry Co Ltd Glykoprotein, forfarande for framstellning derav samt terapeutiskt medel innehallande nemnda glykoprotein
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS60228422A (ja) * 1984-04-26 1985-11-13 Suntory Ltd 安定化された生理活性物質製剤
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
EP0211899B1 (en) * 1985-02-05 1992-09-23 Cetus Oncology Corporation Purification of native colony stimulating factor-1
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤

Also Published As

Publication number Publication date
DK368387A (da) 1988-01-19
NL8701640A (nl) 1988-02-16
SE8702907D0 (sv) 1987-07-17
IT1218927B (it) 1990-04-24
GB8716904D0 (en) 1987-08-26
FR2601591B1 (fr) 1991-04-26
DK368387D0 (da) 1987-07-15
SG64393G (en) 1993-08-06
DE3723781C2 (de) 1999-09-02
AT402259B (de) 1997-03-25
HUT44941A (en) 1988-05-30
YU134287A (en) 1989-06-30
NL192917B (nl) 1998-01-05
NO872966L (no) 1988-01-19
GB2193631A (en) 1988-02-17
KR880001297A (ko) 1988-04-22
YU47543B (sh) 1995-10-03
AU7566587A (en) 1988-01-21
IT8767594A0 (it) 1987-07-10
DK171308B1 (da) 1996-09-02
NO872966D0 (no) 1987-07-16
FR2601591A1 (fr) 1988-01-22
SE503312C2 (sv) 1996-05-13
PT85343B (pt) 1990-04-30
CA1297007C (en) 1992-03-10
DE3723781A1 (de) 1988-01-21
CH671157A5 (de) 1989-08-15
IE60290B1 (en) 1994-06-29
NO171828B (no) 1993-02-01
NO171828C (no) 1993-05-12
CN1033738C (zh) 1997-01-08
CN87104963A (zh) 1988-02-24
GB2193631B (en) 1990-11-21
ATA177587A (de) 1996-08-15
AU611856B2 (en) 1991-06-27
HU198627B (en) 1989-11-28
ES2010226A6 (es) 1989-11-01
HK64893A (en) 1993-07-16
IL83220A0 (en) 1987-12-31
GR871067B (en) 1987-11-19
PT85343A (en) 1987-08-01
SE8702907L (sv) 1988-01-19
KR930004597B1 (ko) 1993-06-01
IE871933L (en) 1988-01-18
BE1000253A3 (fr) 1988-09-27
IL83220A (en) 1993-01-31

Similar Documents

Publication Publication Date Title
NL192917C (nl) Stabiele farmaceutische bereiding die granulocytkolonie-stimulerende factor bevat.
US5919443A (en) Stable lyophilized pharmaceutical preparations of G-CSF
EA012205B1 (ru) Гидрогелевые препараты интерферона
JPH08245418A (ja) 安定なトランスグルタミナーゼ製剤およびそれらを製造する方法
JP2577744B2 (ja) 安定な顆粒球コロニ−刺激因子含有製剤
US9468685B2 (en) Methods of preparing a liquid formulation of G-CSF
RU2025120C1 (ru) Способ получения препарата, содержащего фактор /g-csf/, стимулирующий рост колоний гранулоцитов
JP2577743B2 (ja) 安定な顆粒球コロニ−刺激因子含有製剤
JPS63146828A (ja) 安定な顆粒球コロニ−刺激因子含有製剤
JP2629000B2 (ja) 安定な顆粒球コロニー刺激因子含有製剤
HU218103B (hu) Nem-glikozilezett, rekombináns humán interleukin-2 redukált alakját tartalmazó, stabilizált gyógyászati készítmény és eljárás előállítására
WO2023233277A1 (en) Lyophilized pharmaceutical compositions of copper histidinate
JP2938074B2 (ja) 表皮生長因子含有安定化組成物
WO2007034509A2 (en) Recombinant granulocyte-colony stimulating factor formulation and process
CN1280856A (zh) 一组稳定生物活性物质组合物及其制备方法

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 20070713